<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03744130</url>
  </required_header>
  <id_info>
    <org_study_id>34A</org_study_id>
    <nct_id>NCT03744130</nct_id>
  </id_info>
  <brief_title>Contrast-enhanced Bowel Ultrasound in Making a Diagnosis and Follow-up of Patients With Inflammatory Bowel Disease</brief_title>
  <official_title>Contrast-enhanced Bowel Ultrasound in Making a Diagnosis and Follow-up of Patients With Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State Scientific Centre of Coloproctology, Russian Federation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State Scientific Centre of Coloproctology, Russian Federation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of SonoVue® in participants with&#xD;
      Crohn's disease and ulcerative colitis to various aspects including type of Inflammatory&#xD;
      Bowel Disease, disease activity, the need for surgical treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient is subjected to clinical, laboratory and endoscopic evaluation, each eligible&#xD;
      patient is assigned to one of the arms:&#xD;
&#xD;
      Arm 1: patients with ulcerative colitis (50 patients) Arm 2: patients with Crohn's disease&#xD;
      (50 patients) In each arm, patients are classified according to clinical an endoscopic&#xD;
      activity of the disease.&#xD;
&#xD;
      Each patient is subjected to ultrasound examination of the bowel using a Philips iU 22&#xD;
      machine according to a standardized protocol:&#xD;
&#xD;
        -  12h fasting period&#xD;
&#xD;
        -  exploratory scanning with the use of convex C5-1 probe&#xD;
&#xD;
        -  detailed scanning with the use of linear L 12-5 probe with Power Doppler&#xD;
&#xD;
        -  choosing a bowel segment with the most prominent changes&#xD;
&#xD;
        -  Contrast-enhanced Ultrasound (CEUS)&#xD;
&#xD;
      CEUS is performed according to the following protocol:&#xD;
&#xD;
        -  administration of drotaverine hydrochloride (No-Spa ®) to reduse excessive peristaltic&#xD;
           movement&#xD;
&#xD;
        -  visualization of the previously chosen affected bowel segment with the use of DCE-US&#xD;
           (Dynamic Contrast-Enhanced Ultrasound) technology&#xD;
&#xD;
        -  administration of 2.4 ml SonoVue® intravenously with a bolus injection through a&#xD;
           peripheric venous line (left antecubital vein), followed by a 10ml 0.9% Natrium Chloride&#xD;
           bolus&#xD;
&#xD;
        -  the video-loop is acquired during contrast agent administration and wash-out (preferable&#xD;
           loop duration - 3 min)&#xD;
&#xD;
        -  the original DICOM loop is sent to a work station Philips QLab platform is used to&#xD;
           acquire a fitted Local Density Random Walk Wash-in Wash-out algorithm (LDRWIWO&#xD;
           algorhithm) time-intensity curve of contrast agent wash-in and wash-out. Qualitative and&#xD;
           quantitative (Time to peak, Rise time, Mean transit time, Wash-in Slope, Peak intensity,&#xD;
           Area under curve, Time from peak to one half) parameters are calculated for each region&#xD;
           of interest (ROI).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between contrast-enhanced ultrasound time-intensity curves and endoscopic disease activity</measure>
    <time_frame>[7 days]</time_frame>
    <description>Particular time-intensity curve characteristics (AUC, Peak intensity etc.) could correlate with endoscopic activity of ulcerative colitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between contrast-enhanced ultrasound time-intensity curves in patients with Crohn disease and fibrosis grade according to morphologic analysis of the resected bowel segment</measure>
    <time_frame>[14 days]</time_frame>
    <description>Particular time-intensity curve characteristics could correlate with grade of fibrosis in the resected bowel segment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>patients with UC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with endoscopically proven UC with various extents of disease activity.&#xD;
Diagnostic Test: Contrast-enhanced Ultrasound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with CD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with proven CD with various extents of disease activity Diagnostic Test: Contrast-enhanced Ultrasound</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Contrast-enhanced Ultrasound</intervention_name>
    <description>administration of drotaverine hydrochloride (No-Spa ®) to reduse excessive peristaltic movement&#xD;
visualization of the previously chosen affected bowel segment with the use of DCE-US (Dynamic Contrast-Enhanced Ultrasound) technology&#xD;
administration of 2.4 ml SonoVue® intravenously with a bolus injection through a peripheric venous line (left antecubital vein), followed by a 10ml 0.9% Natrium Chloride bolus&#xD;
the video-loop is acquired during contrast agent administration and wash-out (preferable loop duration - 3 min)&#xD;
the original DICOM loop is sent to a work station</description>
    <arm_group_label>patients with CD</arm_group_label>
    <arm_group_label>patients with UC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with verified UC/CD aged from 18 to 60y&#xD;
&#xD;
          -  signed informed consent form for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  known allergy or history of adverse reaction to sulfur hexafluoride preparations&#xD;
&#xD;
          -  marked pulmonary hypertension&#xD;
&#xD;
          -  uncontrolled hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larisa P Orlova, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Scientific Centre of Coloproctology, Russian Federation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Larisa P Orlova, M.D.</last_name>
    <phone>+7 499 199 66 86</phone>
    <email>lporlova2013@yandex.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>State Scientific Centre of Coloproctology</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larisa P Orlova, M.D.</last_name>
      <phone>+7 499 199 66 86</phone>
      <email>lporlova2013@yandex.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>November 20, 2018</last_update_submitted>
  <last_update_submitted_qc>November 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contrast-enhanced Ultrasound</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>CD</keyword>
  <keyword>UC</keyword>
  <keyword>SonoVue</keyword>
  <keyword>Endoscopic activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

